ClinicalTrials.gov
public full text
Public Domain
A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14 (a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation will be for a total of 28 days.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients#1047531
- Promosi Kesehatan Tentang Pencegahan Infeksi Saluran Pernapasan Akut di Kelurahan Randu#1003613
- Intelligent Lung Support in the Intensive Care Unit#834821
- Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses#876921
- Effect of IAM With an I-gel® on Ventilation Parameters in Simulated Pediatric OHCA#893658
Record · ID 894590
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive